Can finished medicines be sold in the United States when they are registered and listed?
It cannot be judged solely by registration, listing or NDC. The application of listing routes and formulations, labels, quality of production, etc., needs to be confirmed; Products subject to listing should also be checked against the corresponding approval status.
Do brand parties have the same procedures as substitute factories?
It should be judged by their actual activities and regulatory roles. Brands, production facilities, packaging labelling facilities and Labeler may belong to different subjects and cannot replace full responsibility in the supply chain with the same enterprise name.
Is it possible to align the cost of the commitment and the time of completion?
The product path, the integrity of the information and the scope of work need to be checked first, and a distinction made between official FDA costs, testing costs and third-party service costs.
Is it the same thing with Laborer Code, NDC and Drug Listing?
No. Labeler Code, used to identify counterpart drug marketing enterprises, is part of the NDC; The complete NDC also includes product and packaging information, and Drug Listing submits specific drug listings to FDA. (b) The Label Code process needs to be completed before the initial listing or retention of the NDC; Obtaining the code does not amount to a drug being approved.